{"entity":{"id":"nct06646445","kind":"trial","name":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.","aka":["PREMICES"],"tldr":"A phase 2 trial in colorectal cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, not yet recruiting.","summary":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. is a phase 2, randomised interventional study registered as NCT06646445 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 60 participants, started 2025-09 and due to reach its primary completion in 2027-12. Interventions recorded: Pembrolizumab Injection [Keytruda]; Watch-and-wait approach; Surgery; Adjuvant chemotherapy. Conditions listed: Colon Cancer. Primary outcome: The rate of success of the experimental strategy at 6 months or after two successive colonoscopies (corresponding to timepoint at 6 months from the experimental strategy) following randomization.. Colorectal eligibility wording from the registry: \"Newly diagnosed, histologically confirmed colonic or upper third rectal adenocarcinoma, NB: material must be available from biopsy done during colonoscopy\". Sites: France. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06646445","url":"https://clinicaltrials.gov/study/NCT06646445"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gercor"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06646445","phase":"2","setting":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for Patients With Mismatch Repair-deficient or Microsatellite Instability-high (dMMR/MSI-H) Localized Colon Cancer: a Randomized GERCOR G-109 PRODIGE 84 PREMICES Phase II Trial","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06646445/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"company":[{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}